• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Tyme Technologies Inc.

    9/16/22 5:03:51 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TYME alert in real time by email
    S-8 POS 1 d397546ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on September 16, 2022

    Registration No. 333-219856

    Registration No. 333-227077

    Registration No. 333-236259

    Registration No. 333-255253

    Registration No. 333-260912

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Post-Effective Amendment No. 1 to:

    Form S-8 Registration Statement No. 333-219856

    Form S-8 Registration Statement No. 333-227077

    Form S-8 Registration Statement No. 333-236259

    Form S-8 Registration Statement No. 333-255253

    Form S-8 Registration Statement No. 333-260912

    under

    the Securities Act of 1933

     

     

    TYME TECHNOLOGIES, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   45-3864597

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    1 Pluckemin Way, Suite 103, Bedminster, NJ 07921

    (Address of principal executive offices, including zip code)

     

     

    Nancy A. Simonian, M.D.

    President

    TYME TECHNOLOGIES, INC.

    1 Pluckemin Way, Suite 103, Bedminster, NJ 07921

    (Name, Address, including Zip Code, and Telephone Number, including Area Code, of Agent for Service)

     

     

    Copies to:

    Cynthia T. Mazareas, Esq.

    Joseph B. Conahan, Esq.

    Eric P. Hanson, Esq.

    Stephanie L. Leopold, Esq.

    Wilmer Cutler Pickering Hale and Dorr LLP

    60 State Street

    Boston, Massachusetts 02109

    (617) 526-6000

    (Telephone number, including area code, of agent for service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    EXPLANATORY NOTE/DEREGISTRATION OF SECURITIES

    These Post-Effective Amendments (these “Post-Effective Amendments”) relate to the following Registration Statements on Form S-8 (each, a “Registration Statement” and collectively, the “Registration Statements”) filed by Tyme Technologies, Inc., a Delaware corporation (the “Registrant”), with the Securities and Exchange Commission (the “SEC”) to deregister any and all shares of the Registrant’s common stock, par value $0.0001 per share (“Common Stock”), registered but unsold or otherwise unissued under each such Registration Statement as of the date hereof:

     

      1.

    Registration Statement on Form S-8 (File No. 333-219856), filed with the SEC on August 10, 2017, registering 10,000,000 shares of Common Stock issuable under the Registrant’s 2015 Equity Incentive Plan (the “2015 Plan”) and 750,000 shares of Common Stock issuable under the 2016 Stock Option Plan for Non-Employee Directors (the “2016 Plan”).

     

      2.

    Registration Statement on Form S-8 (File No. 333-227077), filed with the SEC on August 28, 2018, registering 2,656,552 shares of Common Stock issuable under the 2015 Plan and 2,000,000 shares of Common Stock issuable under the 2016 Plan.

     

      3.

    Registration Statement on Form S-8 (File No. 333-236259), filed with the SEC on February 5, 2020, registering 2,686,651 shares of Common Stock issuable under the 2015 Plan.

     

      4.

    Registration Statement on Form S-8 (File No. 333-255253), filed with the SEC on April 15, 2021, registering 6,181,877 shares of Common Stock issuable under the 2015 Plan.

     

      5.

    Registration Statement on Form S-8 (File No. 333-260912), filed with the SEC on November 9, 2021, registering 3,000,000 shares of Common Stock issuable under the 2016 Plan.

    On September 16, 2022, pursuant to that certain Agreement and Plan of Merger (the “Merger Agreement”), dated as of July 3, 2022, among the Registrant, Syros Pharmaceuticals, Inc. (“Syros”) and Tack Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Syros (“Merger Sub”), Merger Sub merged with and into the Registrant (the “Merger”), with the Registrant continuing as the surviving entity and a wholly owned subsidiary of Syros. These Post-Effective Amendments are being filed as a result of the Merger.

    The Registrant, by filing these Post-Effective Amendments, hereby terminates the effectiveness of the Registration Statements and removes from registration any and all shares of Common Stock registered but unsold or otherwise unissued under the Registration Statements as of the date hereof. This filing is made in accordance with an undertaking made by the Registrant in Part II of each Registration Statement to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold at the termination of the offering.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on September 16, 2022.

     

    Tyme Technologies, Inc.
    By:  

    /s/ Jason Haas

    Name: Jason Haas
    Title: Treasurer and Secretary

    No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.

    Get the next $TYME alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TYME

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TYME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Sokol Gerald H returned 5,865 shares to the company, closing all direct ownership in the company

    4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)

    9/16/22 6:01:07 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Porfido Frank L. returned 10,000 shares to the company, closing all direct ownership in the company

    4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)

    9/16/22 6:00:57 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Biehl James returned 105,150 shares to the company, closing all direct ownership in the company

    4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)

    9/16/22 6:00:35 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYME
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Syros and Tyme Technologies Announce Stockholder Approval of Merger

    -- Combined Company to Trade on Nasdaq Under Ticker "SYRS" ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME's special meeting, TYME's stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the "Merger Agreement"), pu

    9/15/22 4:13:00 PM ET
    $SYRS
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syros and Tyme Technologies Announce Stockholder Approval of Merger

    -- Combined Company to Trade on Nasdaq Under Ticker "SYRS" -- -- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME's special meeting, TYME's stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the "Merger Agreement"), pursuant to which a direct, wholly owned subsidiary of Syros will merge with

    9/15/22 4:01:00 PM ET
    $SYRS
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TYME Technologies, Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote "FOR" Proposed Merger of Syros and Tyme

    BEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) ("Tyme" or the "Company"), today announced that independent proxy advisory firms Glass, Lewis & Co. ("Glass Lewis") and Institutional Shareholder Services Inc. ("ISS") have recommended that Tyme stockholders vote "FOR" the previously announced merger of Tyme and Syros Pharmaceuticals, Inc. ("Syros") and "FOR" all other matters to be voted upon at the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for September 15, 2022 at 11:00 a.m., Eastern Time. ISS and Glass Lewis are leading independent, third-party proxy advisory firms who, among other services, provide pro

    9/7/22 8:00:00 AM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYME
    SEC Filings

    View All

    SEC Form 15-12G filed by Tyme Technologies Inc.

    15-12G - TYME TECHNOLOGIES, INC. (0001537917) (Filer)

    9/30/22 4:05:54 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Tyme Technologies Inc.

    EFFECT - TYME TECHNOLOGIES, INC. (0001537917) (Filer)

    9/22/22 12:15:06 AM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Tyme Technologies Inc.

    EFFECT - TYME TECHNOLOGIES, INC. (0001537917) (Filer)

    9/22/22 12:15:20 AM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYME
    Financials

    Live finance-specific insights

    View All

    Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement

    Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros' Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023 Syros to Host Conference Call at 8:30 AM ET Today Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire TYME, including its pipeline assets and net cash at closing which after accounting for wind-dow

    7/5/22 7:00:00 AM ET
    $SYRS
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results

    – Georgetown University and associated Georgetown Medstar Centers continued enrollment in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor – On track for mid-2022 full enrollment of HopES trial for SM-88 used in patients with high-risk Ewing's and other sarcoma types – Pursuing options to diversify the clinical pipeline – Well-capitalized position, with $92.0 million in cash and marketable securities as of December 31, 2021 – Company to host live conference call and webcast today, February 11, at 8:30 AM ET TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emer

    2/11/22 6:50:00 AM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET

    TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Friday, February 11, 2022 Time: 8:30 AM ET Toll-free (U.S.) (866) 601-3896 International (636) 812-6499 Conference ID 1286376 The webcast will be accessible on the Events & Presentations page of the Investors s

    1/27/22 4:30:00 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Tyme Technologies Inc. (Amendment)

    SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)

    9/16/22 4:34:58 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Tyme Technologies Inc. (Amendment)

    SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)

    2/8/22 7:00:52 AM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)

    2/12/21 4:07:03 PM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYME
    Leadership Updates

    Live Leadership Updates

    View All

    TYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical Officer

    BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the appointment of Jan M Van Tornout, MD, MSc, as acting Chief Medical Officer, effective April 1, 2021. Dr. Van Tornout will provide leadership and direction for all medical and related preclinical programs in development. He will be replacing Dr. Giuseppe Del Priore. “On behalf of the board of directors, we truly appreciate Giuseppe’s many contributions towards advancing our programs and we wish him continued success in his future endeavors,” said Richie Cunningham, TYME’s CEO. Dr. Van Tornout brings

    4/1/21 8:00:00 AM ET
    $TYME
    Biotechnology: Pharmaceutical Preparations
    Health Care